1. Regiospecific Synthesis of Ring A Fused Withaferin A Isoxazoline Analogues: Induction of Premature Senescence by W-2b in Proliferating Cancer Cells.
- Author
-
Rasool F, Nayak D, Katoch A, Faheem MM, Yousuf SK, Hussain N, Belawal C, Satti NK, Goswami A, and Mukherjee D
- Subjects
- Animals, Antineoplastic Agents chemistry, Apoptosis, Breast Neoplasms metabolism, Cell Cycle, Cell Proliferation, Checkpoint Kinase 2 metabolism, Female, Gene Expression Regulation, Neoplastic, Humans, Isoxazoles chemistry, Mice, Mice, Inbred BALB C, Mice, Nude, Signal Transduction, Tumor Cells, Cultured, Withanolides chemistry, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Cellular Senescence drug effects, Isoxazoles pharmacology, Withanolides pharmacology
- Abstract
Induction of premature senescence represents a novel functional strategy to curb the uncontrolled proliferation of malignant cancer cells. This study unveils the regiospecific synthesis of novel isoxazoline derivatives condensed to ring A of medicinal plant product Withaferin-A. Intriguingly, the cis fused products with β-oriented hydrogen exhibited excellent cytotoxic activities against proliferating human breast cancer MCF7 and colorectal cancer HCT-116 cells. The most potent derivative W-2b triggered premature senescence along with increase in senescence-associated β-galactosidase activity, G2/M cell cycle arrest, and induction of senescence-specific marker p21
Waf1/Cip1 at its sub-toxic concentration. W-2b conferred a robust increase in phosphorylation of mammalian checkpoint kinase-2 (Chk2) in cancer cells in a dose-dependent manner. Silencing of endogenous Chk2 by siRNA divulged that the amplification of p21 expression and senescence by W-2b was Chk2-dependent. Chk2 activation (either by ectopic overexpression or through treatment with W-2b) suppressed NM23-H1 signaling axis involved in cancer cell proliferation. Finally, W-2b showed excellent in vivo efficacy with 83.8% inhibition of tumor growth at a dose of 25 mg/kg, b.w. in mouse mammary carcinoma model. Our study claims that W-2b could be a potential candidate to limit aberrant cellular proliferation rendering promising improvement in the treatment regime in cancer patients.- Published
- 2017
- Full Text
- View/download PDF